Home Hematology and Oncology Overall Survival Up With Surgical Treatment in T3 Glottic SCC

Overall Survival Up With Surgical Treatment in T3 Glottic SCC

Improved OS for surgery alone, surgery with adjuvant treatment versus nonsurgical management

MONDAY, July 11, 2016 (HealthDay News) — Patients with T3 glottic squamous cell carcinoma (SCC) have improved overall survival (OS) with surgical treatment versus nonsurgical management, according to a study published online July 7 in JAMA Otolaryngology-Head & Neck Surgery.

Maha Al-Gilani, M.B.B.S., from the Washington University School of Medicine in St. Louis, and colleagues compared OS and functional outcomes in a secondary analysis using data from patients with T3 glottic SCC receiving nonsurgical and surgical management.

The researchers found that the five-year OS was 36, 41, and 41 percent, respectively, for nonsurgical management, surgery alone, and surgery plus adjuvant treatment. In multivariable analyses, the adjusted hazard ratios for OS were 0.68 and 0.75 for patients receiving surgery alone versus nonsurgical management and for patients receiving surgery plus adjuvant treatment versus nonsurgical management, respectively. Patients receiving surgery plus nonadjuvant treatment had the highest gastrostomy tube dependence (30.6 percent). Patients receiving chemoradiotherapy had the highest tracheostomy dependence (37 percent).

“Overall survival showed a statistically significant and clinically meaningful improvement in patients with T3 glottic SCC who underwent surgery compared with a nonsurgical treatment,” the authors write. “Furthermore, the data suggest that adjuvant and nonsurgical treatment result in a dysfunctional larynx; however, this association needs further study.”

Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.